Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its pricey next-generation cell and gene therapies.
The U.S. Food and Drug Administration (FDA) has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to enhance the development of medical products for patients with rare diseases.
Protalex announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the Company a $403,000 grant to support future clinical development activity of PRTX-100 as a treatment for Immune Thrombocytopenia (IT